Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Quizartinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 known ✓ | P36888 | 20/20 | 1.00 |
| ▸ | CSF1R known ✓ | P07333 | 1/20 | 0.99 |
| ▸ | RET known ✓ | P07949 | 1/20 | 0.99 |
| ▸ | PDGFRB known ✓ | P09619 | 1/20 | 0.99 |
| ▸ | KIT known ✓ | P10721 | 1/20 | 0.99 |
| ▸ | PDGFRA known ✓ | P16234 | 1/20 | 0.99 |
| ▸ | KDR | P35968 | 2/20 | 1.00 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.99 |
| ▸ | MUSK | O15146 | 1/20 | 0.99 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.99 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.99 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.99 |
| ▸ | PAK3 | O75914 | 1/20 | 0.99 |
| ▸ | STK10 | O94804 | 1/20 | 0.99 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.99 |
| ▸ | ABL1 | P00519 | 1/20 | 0.99 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.99 |
| ▸ | LCK | P06239 | 1/20 | 0.99 |
| ▸ | YES1 | P07947 | 1/20 | 0.99 |
| ▸ | LYN | P07948 | 1/20 | 0.99 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Quizartinib SCHEMBL29435035 | 1.00 | FLT3 (1.00) | FLT3KDRBMPR1BMUSKEPHB6 | |
| Quizartinib SCHEMBL74121 | 1.00 | FLT3 (1.00) | FLT3KDRBMPR1BMUSKEPHB6 | |
| Quizartinib SCHEMBL72923 | 0.99 | FLT3 (1.00) | FLT3KDRBMPR1BMUSKEPHB6 | |
| Quizartinib SCHEMBL29349937 | 0.99 | FLT3 (1.00) | FLT3KDRBMPR1BMUSKEPHB6 | |
| Hydrochloric Acid SCHEMBL3453696 | 0.97 | FLT3 (0.99) | FLT3KDRBMPR1BMUSKEPHB6 | |
| SCHEMBL73633 | 0.96 | FLT3 (1.00) | FLT3KDRBMPR1BMUSKEPHB6 | |
| Hydrochloric Acid SCHEMBL742748 | 0.95 | FLT3 (0.99) | FLT3KDRBMPR1BMUSKEPHB6 | |
| Hydrochloric Acid SCHEMBL74122 | 0.95 | FLT3 (0.99) | FLT3KDRBMPR1BMUSKEPHB6 | |
| SCHEMBL72924 | 0.94 | FLT3 (1.00) | FLT3KDRBMPR1BMUSKEPHB6 | |
| Hydrochloric Acid SCHEMBL74399 | 0.94 | FLT3 (0.99) | FLT3KDRBMPR1BMUSKEPHB6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 244 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4743086-A2 | TREATING MYELOID DISORDERS | Mayo Foundation for Medical Education and Research (US) | 2026-05-20 | — | — | EP | claimed |
| EP-4638443-A1 | TRANSIENT RECEPTOR POTENTIAL VANILLOID 6 INHIBITORS | Uniquest Pty Limited (AU) | 2025-10-29 | — | — | EP | claimed |
| WO-2025015263-A2 | TREATING MYELOID DISORDERS | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2025-01-16 | — | — | WO | claimed |
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| WO-2024130344-A1 | TRANSIENT RECEPTOR POTENTIAL VANILLOID 6 INHIBITORS | UNIQUEST PTY LIMITED (AU) | 2024-06-27 | — | — | WO | claimed |
| EP-3260119-B1 | COMBINATION METHOD FOR TREATING CANCER | DAIICHI SANKYO CO LTD (JP) | 2023-11-15 | — | — | EP | claimed |
| US-10716790-B2 | Method for treating cancer by combined use | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2020-07-21 | — | — | US | claimed |
| EP-2521782-B1 | FLT3 RECEPTOR ANTAGONISTS FOR THE TREATMENT OR THE PREVENTION OF PAIN DISORDERS | INST NAT SANTE RECH MED (FR) | 2019-04-10 | — | — | EP | claimed |
| EP-2903593-B1 | TABLET CONTAINING COMPOSITE WITH CYCLODEXTRIN | AMBIT BIOSCIENCES CORP (US) | 2018-03-21 | — | — | EP | claimed |
| EP-3260119-A1 | COMBINATION METHOD FOR TREATING CANCER | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-12-27 | — | — | EP | claimed |
| US-20170216302-A1 | METHOD FOR TREATING CANCER BY COMBINED USE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-08-03 | — | — | US | claimed |
| US-9675549-B2 | Tablet containing composite with cyclodextrin | AMBIT BIOSCIENCES CORPORATION (US) | 2017-06-13 | — | — | US | claimed |
| US-20150250720-A1 | TABLET CONTAINING COMPOSITE WITH CYCLODEXTRIN | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-09-10 | — | — | US | claimed |
| US-9109227-B2 | FLT3 receptor antagonists for the treatment or the prevention of pain disorders | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2015-08-18 | — | — | US | claimed |
| EP-4743086-A2 | TREATING MYELOID DISORDERS | Mayo Foundation for Medical Education and Research (US) | 2026-05-20 | — | — | EP | disclosed |
| US-20260130893-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES INC (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4735445-A1 | KRAS MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-2429524-A1 | METHODS OF TREATING PROLIFERATIVE DISEASES | Ambit Biosciences Corporation (US) | 2012-03-21 | — | — | EP | disclosed |
| WO-2011083124-A1 | FLT3 RECEPTOR ANTAGONISTS FOR THE TREATMENT OR THE PREVENTION OF PAIN DISORDERS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2011-07-14 | — | — | WO | disclosed |
| WO-2010132787-A1 | METHODS OF TREATING PROLIFERATIVE DISEASES | AMBIT BIOSCIENCES CORPORATION (US) | 2010-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150250720-A1 | TABLET CONTAINING COMPOSITE WITH CYCLODEXTRIN | HBZ, MCL1, HBB | FLT3 23/4885CSF1R 2846/4885RET 2600/4885 |
| US-20260130893-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | FLT3 1906/4885CSF1R 1226/4885RET 892/4885 |
| US-20170216302-A1 | METHOD FOR TREATING CANCER BY COMBINED USE | FLT3, MDM2, TP53 | FLT3 1/4885CSF1R 185/4885RET 78/4885 |
| US-10716790-B2 | Method for treating cancer by combined use | FLT3, MDM2, TP53 | FLT3 1/4885CSF1R 185/4885RET 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.